Skip to content
+1-516-222-6222
LCS@lachmanconsultants.com
Search
Location Selector

Current Location

  • - Global Website

  • - Ireland Website
  • About
    • Lachman Leadership Team
    • Lachman Board of Directors
  • Areas Served
    • Pharmaceutical
    • Medical Device & Combination Products
    • Biologics
    • Regulatory Affairs
  • Services
    • FDA-Related Services
    • Compliance
    • FDA 483 Response
    • Data Integrity
    • Mock FDA Inspections
    • Analytical Services
    • Biomonitoring Support
    • Strategic Planning
    • Due Diligence Audits
    • Quality Assurance and Controls
    • Scientific and Technical Assistance
    • Systems Evaluation
    • Facilities Design or Validation
    • System Process Validation or Qualification
    • Training
    • Remote Services From Lachman
  • Markets
    • Pharmaceuticals
    • Medical Devices
    • Combination Products
    • Biotechnology
    • Biologics
    • Diagnostics
    • Generics & Biosimilars
    • Related Industries
  • Blog
  • News
  • Contact
  • Careers
    • Career Opportunities
  • Resources
    • Lachman Learning
  • Location Selector
    • – Global Website
    • – Ireland Website

DTC

Lachman Consultant Services, Inc. / Blog / DTC
20
Nov

Prescription Drug Advertising – Final Rule Issued on DTC Ads 

By Bob Pollock    Nov 20, 2023    Advertising DTC Labeling NDA

I am sure that any of you that have listened to radio or watched TV have heard a prescription drug ad and  have struggled with keeping up with the fast talking and not so slow walking people, scene, or scrolling of text on direct-to-consumer ads.  FDA has been working to develop standards over the course […]

Read More

Subscribe to our blog

Recent Articles

  • Fluoride Rx Products Take a Hit as FDA Plans Removal from the Marketplace
  • Priority Review Vouchers a Hot Commodity
  • Reflections from the PDA Pharmaceutical Manufacturing and Quality Conference 2025–Singapore

Contact Us:



Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA and industry experts has offered compliance, regulatory affairs, and technical services to clients around the world.
+1-516-222-6222
LCS@lachmanconsultants.com

 

Subscribe to our blog

Quick Links

  • Home
  • About
  • Services
  • Areas Served
  • Markets
  • Careers
  • Blog
  • Contact

Recent Posts

  • Finance concept Proposed action text with thumb up symbol on yellow-colored backgroundFluoride Rx Products Take a Hit as FDA Plans Remov…
    May 13, 2025
  • US Food and Drug Administration (FDA)Priority Review Vouchers a Hot Commodity
    May 12, 2025
  • Reflections from the PDA Pharmaceutical Manufacturing and Quality Conference 2025 - Lachman BlogReflections from the PDA Pharmaceutical Manufactur…
    May 9, 2025
2025 © Lachman Consultant Services, Inc.Terms and ConditionsPrivacy Policy
  • About
    ▼
    • Lachman Leadership Team
    • Lachman Board of Directors
  • Areas Served
    ▼
    • Pharmaceutical
    • Medical Device & Combination Products
    • Biologics
    • Regulatory Affairs
  • Services
    ▼
    • FDA-Related Services
    • Compliance
    • FDA 483 Response
    • Data Integrity
    • Mock FDA Inspections
    • Analytical Services
    • Biomonitoring Support
    • Strategic Planning
    • Due Diligence Audits
    • Quality Assurance and Controls
    • Scientific and Technical Assistance
    • Systems Evaluation
    • Facilities Design or Validation
    • System Process Validation or Qualification
    • Training
    • Remote Services From Lachman
  • Markets
    ▼
    • Pharmaceuticals
    • Medical Devices
    • Combination Products
    • Biotechnology
    • Biologics
    • Diagnostics
    • Generics & Biosimilars
    • Related Industries
  • Blog
  • News
  • Contact
  • Careers
    ▼
    • Career Opportunities
  • Resources
    ▼
    • Lachman Learning
  • Location Selector
    ▼
    • – Global Website
    • – Ireland Website